• KEEP LIFE FLOWING

    Kedrion’s plasma-derived therapies help people suffering from rare diseases like Hemophilia and Primary Immune Deficiencies. We are privileged to provide this service and do so with a profound sense of responsibility.

  • KEEP LIFE FLOWING

    Kedrion’s plasma-derived therapies help people suffering from rare diseases like Hemophilia and Primary Immune Deficiencies. We are privileged to provide this service and do so with a profound sense of responsibility.

  • KEEP LIFE FLOWING

    Kedrion’s plasma-derived therapies help people suffering from rare diseases like Hemophilia and Primary Immune Deficiencies. We are privileged to provide this service and do so with a profound sense of responsibility.

News

The world of Kedrion Biopharma at a glance:
discover the latest
up-to-date news.

All news.
02-12-2021
Kedrion Biopharma to commercialize RYPLAZIM® in U.S
RYPLAZIM® (plasminogen, human-tvmh) will address needs in patients with ultra-rare condition Plasminogen Deficiency Type 1
Read all
18-10-2021
Kedrion grows in North America as it completes acquisition of Prometic
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency
Read all
04-06-2021
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update
KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children
Read all
Pharmacovigilange
Medical & Scientific Information
2020 Annual report